American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 825-830.e1 , May 2009

Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular Degeneration

  • Panagiotis G. Theodossiadis

      Affiliations

    • Attikon University Hospital, 2nd Department of Ophthalmology, University of Athens, Athens, Greece
    • Corresponding Author InformationInquiries to Panagiotis G. Theodossiadis, 13 Lykiou Street, 10675 Athens, Greece
    • ,
  • Vasilios S. Liarakos

      Affiliations

    • Attikon University Hospital, 2nd Department of Ophthalmology, University of Athens, Athens, Greece
    • ,
  • Petros P. Sfikakis

      Affiliations

    • Laikon Hospital, 1st Department of Propedeutic Medicine, University of Athens, Athens, Greece
    • ,
  • Ioannis A. Vergados

      Affiliations

    • Attikon University Hospital, 2nd Department of Ophthalmology, University of Athens, Athens, Greece
    • ,
  • George P. Theodossiadis

      Affiliations

    • Department of Ophthalmology, Henry Dynan Hospital, Athens, Greece

,Accepted 2 December 2008.

References 

  1. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  2. Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;CD005139
  3. Nussenblatt RB, Ferris F. Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol. 2007;144:618–626
  4. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891–1898
  5. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 1998;212:410–414
  6. Jin M, He S, Worpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha. Invest Ophthalmol Vis Sci. 2000;41:4324–4332
  7. Yang P, McKay BS, Allen JB, Jaffe GJ. Effect of NF-kappa B inhibition on TNF-alpha-induced apoptosis in human RPE cells. Invest Ophthalmol Vis Sci. 2004;45:2438–2446
  8. Yang P, Wiser JL, Peairs JJ, et al. Human RPE expression of cell survival factors. Invest Ophthalmol Vis Sci. 2005;46:1755–1764
  9. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404–406
  10. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295–296
  11. Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895–900
  12. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol. 2005;139:537–540
  13. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 2004;50:1636–1641
  14. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009;247:273–281
  15. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27:399–413
  16. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–2518
  17. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–912
  18. Wegscheider BJ, El-Shabrawi L, Weger M, et al. Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye. 2007;21:547–549
  19. Keystone EC. Safety of biologic therapies–an update. J Rheumatol Suppl. 2005;74:8–12
  20. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:260–266
  21. Ueda T, Ueda T, Fukuda S, et al. Lipid hydroperoxide-induced tumor necrosis factor (TNF)-alpha, vascular endothelial growth factor and neovascularization in the rabbit cornea: effect of TNF inhibition. Angiogenesis. 1998;1:174–184
  22. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007;125:1221–1224
  23. Shi X, Semkova I, Muther PS, et al. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res. 2006;83:1325–1334
  24. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008;49:1151–1156
  25. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131–136
  26. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, et al. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol. 2007;22:75–79
  27. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–1257
  28. Manzano RP, Peyman GA, Carvounis PE, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2008;246:907–911
  29. Van Laar JA, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behcet's disease?. Ann Rheum Dis. 2007;66:565–566
  30. Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47:339–344
  31. Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–361

 See accompanying Editorial on page 761.

PII: S0002-9394(08)00921-5

doi: 10.1016/j.ajo.2008.12.004

American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 825-830.e1 , May 2009

Article Tools

* Image Usage & Resolution